Jonathan M. Brotchie - Publications

Affiliations: 
Toronto Western Research Institute, Toronto, Ontario, Canada 
Area:
neurodegenerative disorders

186 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Howson PA, Johnston TH, Ravenscroft P, Hill MP, Su J, Brotchie JM, Koprich JB. Beneficial effects of trehalose on striatal dopaminergic deficits in rodent and primate models of synucleinopathy in Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics. PMID 30918068 DOI: 10.1124/jpet.118.255695  0.88
2018 Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR. Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 30575996 DOI: 10.1002/mds.27565  0.88
2018 Fox SH, Brotchie JM. Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold? The European Journal of Neuroscience. PMID 30269407 DOI: 10.1111/ejn.14173  0.56
2018 Johnston TH, Lacoste AMB, Visanji NP, Lang AE, Fox SH, Brotchie JM. Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease. Neuropharmacology. PMID 29907424 DOI: 10.1016/j.neuropharm.2018.05.035  0.56
2018 Gleave JA, Arathoon LR, Trinh D, Lizal KE, Giguère N, Barber JEM, Najarali Z, Hassan Khan M, Thiele SL, Semmen MS, Koprich JB, Brotchie JM, Eubanks JH, Trudeau LE, Nash JE. Corrigendum to "Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism" [Neurobiol. Dis. 106 (2018) 133-146]. Neurobiology of Disease. PMID 29571591 DOI: 10.1016/j.nbd.2018.02.018  0.52
2017 Johnston TH, Versi E, Howson PA, Ravenscroft P, Fox SH, Hill MP, Reidenberg BE, Corey R, Brotchie JM. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease. Neuropharmacology. PMID 29197517 DOI: 10.1016/j.neuropharm.2017.11.046  0.88
2017 Arathoon LR, Gleave JA, Trinh D, Lizal KE, Giguère N, Barber JHM, Najarali Z, Hassan Khan M, Thiele SL, Semmen MS, Koprich JB, Brotchie JM, Eubanks JH, Trudeau LE, Nash JE. Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism. Neurobiology of Disease. PMID 28673739 DOI: 10.1016/j.nbd.2017.06.009  0.52
2016 Huot P, Fox SH, Brotchie JM. Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of Nonhuman Primate Studies and Clinical Trials. The Journal of Pharmacology and Experimental Therapeutics. 357: 562-9. PMID 27190169 DOI: 10.1124/jpet.116.232371  1
2015 Ma Y, Johnston TH, Peng S, Zuo C, Koprich JB, Fox SH, Guan Y, Eidelberg D, Brotchie JM. Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 1283-8. PMID 26377152 DOI: 10.1002/mds.26302  0.56
2015 Kim HK, Mendonça KM, Howson PA, Brotchie JM, Andreazza AC. The link between mitochondrial complex I and brain-derived neurotrophic factor in SH-SY5Y cells - The potential of JNX1001 as a therapeutic agent. European Journal of Pharmacology. 764: 379-84. PMID 26164791 DOI: 10.1016/j.ejphar.2015.07.013  1
2015 Huot P, Johnston TH, Fox SH, Newman-Tancredi A, Brotchie JM. The highly-selective 5-HT1A agonist F15599 reduces l-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque. Neuropharmacology. 97: 306-11. PMID 26071982 DOI: 10.1016/j.neuropharm.2015.05.033  1
2015 He Q, Koprich JB, Wang Y, Yu WB, Xiao BG, Brotchie JM, Wang J. Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease. Molecular Neurobiology. PMID 25972237 DOI: 10.1007/s12035-015-9173-7  1
2015 Huot P, Fox SH, Brotchie JM. Monoamine reuptake inhibitors in Parkinson's disease. Parkinson's Disease. 2015: 609428. PMID 25810948 DOI: 10.1155/2015/609428  1
2015 Phookan S, Sutton AC, Walling I, Smith A, O'Connor KA, Campbell JC, Calos M, Yu W, Pilitsis JG, Brotchie JM, Shin DS. Gap junction blockers attenuate beta oscillations and improve forelimb function in hemiparkinsonian rats. Experimental Neurology. 265: 160-70. PMID 25622779 DOI: 10.1016/j.expneurol.2015.01.004  1
2015 Huot P, Johnston TH, Fox SH, Brotchie JM. Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot study. Synapse (New York, N.Y.). 69: 99-102. PMID 25559284 DOI: 10.1002/syn.21801  1
2015 Huot P, Johnston TH, Koprich JB, Espinosa MC, Reyes MG, Fox SH, Brotchie JM. L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat. Behavioural Pharmacology. 26: 101-8. PMID 25303957 DOI: 10.1097/FBP.0000000000000096  1
2014 Thiele SL, Chen B, Lo C, Gertler TS, Warre R, Surmeier JD, Brotchie JM, Nash JE. Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models. Neurobiology of Disease. 71: 334-44. PMID 25171793 DOI: 10.1016/j.nbd.2014.08.006  1
2014 Arumugaswamy A, He S, Quach H, Brotchie J, Grigg A. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration Internal Medicine Journal. 44: 519-521. PMID 24816314 DOI: 10.1111/imj.12406  1
2014 Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM. UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset. Neuropharmacology. 82: 76-87. PMID 24447715 DOI: 10.1016/j.neuropharm.2014.01.012  1
2014 Fox SH, Brotchie JM, Johnston TM. Primate Models of Complications Related to Parkinson Disease Treatment Movement Disorders: Genetics and Models: Second Edition. 355-371. DOI: 10.1016/B978-0-12-405195-9.00021-4  1
2014 Brotchie JM, Fox SH. Final thoughts: Summary and future therapeutic strategies in levodopa-induced dyskinesia Levodopa-Induced Dyskinesia in Parkinson's Disease. 355-359. DOI: 10.1007/978-1-4471-6503-3_19  1
2014 Fox SH, Brotchie JM. Preface Levodopa-Induced Dyskinesia in Parkinson's Disease. v. DOI: 10.1007/978-1-4471-6503-3  1
2013 Eskow Jaunarajs KL, Standaert DG, Viegas TX, Bentley MD, Fang Z, Dizman B, Yoon K, Weimer R, Ravenscroft P, Johnston TH, Hill MP, Brotchie JM, Moreadith RW. Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 1675-82. PMID 24014074 DOI: 10.1002/mds.25625  1
2013 Johnston TH, Huot P, Fox SH, Koprich JB, Szeliga KT, James JW, Graef JD, Letchworth SR, Jordan KG, Hill MP, Brotchie JM. TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque. Neuropharmacology. 73: 337-47. PMID 23770260 DOI: 10.1016/j.neuropharm.2013.06.005  1
2013 Kirshenbaum GS, Dawson N, Mullins JG, Johnston TH, Drinkhill MJ, Edwards IJ, Fox SH, Pratt JA, Brotchie JM, Roder JC, Clapcote SJ. Alternating hemiplegia of childhood-related neural and behavioural phenotypes in Na+,K+-ATPase α3 missense mutant mice. Plos One. 8: e60141. PMID 23527305 DOI: 10.1371/journal.pone.0060141  1
2013 Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Pharmacological Reviews. 65: 171-222. PMID 23319549 DOI: 10.1124/pr.111.005678  1
2013 Koprich JB, Huot P, Fox SH, Jarvie K, Lang AE, Seeman P, Brotchie JM. The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 43: 151-6. PMID 23306217 DOI: 10.1016/j.pnpbp.2012.12.008  1
2013 Huot P, Johnston TH, Snoeren T, Koprich JB, Hill MP, Fox SH, Brotchie JM. Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque. The European Journal of Neuroscience. 37: 831-8. PMID 23281915 DOI: 10.1111/ejn.12093  1
2013 Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 131-44. PMID 23225267 DOI: 10.1002/mds.25273  1
2013 Sutton AC, Yu W, Calos ME, Mueller LE, Berk M, Shim J, Molho ES, Brotchie JM, Carlen PL, Shin DS. Elevated potassium provides an ionic mechanism for deep brain stimulation in the hemiparkinsonian rat. The European Journal of Neuroscience. 37: 231-41. PMID 23121286 DOI: 10.1111/ejn.12040  1
2013 Lang M, Wither RG, Brotchie JM, Wu C, Zhang L, Eubanks JH. Selective preservation of MeCP2 in catecholaminergic cells is sufficient to improve the behavioral phenotype of male and female Mecp2-deficient mice. Human Molecular Genetics. 22: 358-71. PMID 23077217 DOI: 10.1093/hmg/dds433  1
2013 Sutton AC, Yu W, Calos ME, Smith AB, Ramirez-Zamora A, Molho ES, Pilitsis JG, Brotchie JM, Shin DS. Deep brain stimulation of the substantia nigra pars reticulata improves forelimb akinesia in the hemiparkinsonian rat. Journal of Neurophysiology. 109: 363-74. PMID 23076106 DOI: 10.1152/jn.00311.2012  1
2013 Johnston TH, Huot P, Damude S, Fox SH, Jones SW, Rusche JR, Brotchie JM. RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study. Parkinsonism & Related Disorders. 19: 260-4. PMID 22901956 DOI: 10.1016/j.parkreldis.2012.07.001  1
2012 Huot P, Johnston TH, Gandy MN, Reyes MG, Fox SH, Piggott MJ, Brotchie JM. The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset. Plos One. 7: e45587. PMID 23029119 DOI: 10.1371/journal.pone.0045587  1
2012 Fox SH, Johnston TH, Li Q, Brotchie J, Bezard E. A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 1373-8. PMID 22976821 DOI: 10.1002/mds.25133  1
2012 Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease. Neuropharmacology. 63: 829-36. PMID 22722022 DOI: 10.1016/j.neuropharm.2012.06.012  1
2012 Huot P, Johnston TH, Koprich JB, Aman A, Fox SH, Brotchie JM. L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics. 342: 576-85. PMID 22619253 DOI: 10.1124/jpet.112.195693  1
2012 Marras C, Gruneir A, Rochon P, Wang X, Anderson G, Brotchie J, Bell CM, Fox S, Austin PC. Dihydropyridine calcium channel blockers and the progression of parkinsonism. Annals of Neurology. 71: 362-9. PMID 22451203 DOI: 10.1002/ana.22616  1
2012 Huot P, Johnston TH, Visanji NP, Darr T, Pires D, Hazrati LN, Brotchie JM, Fox SH. Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 735-42. PMID 22419526 DOI: 10.1002/mds.24964  1
2012 Johnston TH, Millar Z, Huot P, Wagg K, Thiele S, Salomonczyk D, Yong-Kee CJ, Gandy MN, McIldowie M, Lewis KD, Gomez-Ramirez J, Lee J, Fox SH, Martin-Iverson M, Nash JE, ... ... Brotchie JM, et al. A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 26: 2154-63. PMID 22345403 DOI: 10.1096/fj.11-195016  1
2012 Rascol O, Ferreira J, Nègre-Pages L, Perez-Lloret S, Lacomblez L, Galitzky M, Lemarié JC, Corvol JC, Brotchie JM, Bossi L. A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson's disease. Fundamental & Clinical Pharmacology. 26: 557-64. PMID 21585523 DOI: 10.1111/j.1472-8206.2011.00951.x  1
2012 Alachkar A, Brotchie JM, Jones OT. Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of Parkinson's disease and L-DOPA-induced dyskinesia. Journal of Molecular Neuroscience : Mn. 46: 145-52. PMID 21562737 DOI: 10.1007/s12031-011-9539-x  1
2012 Huot P, Johnston TH, Koprich JB, Winkelmolen L, Fox SH, Brotchie JM. Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque. Neurobiology of Aging. 33: 207.e9-19. PMID 21051107 DOI: 10.1016/j.neurobiolaging.2010.09.011  1
2012 Huot P, Johnston TH, Winkelmolen L, Fox SH, Brotchie JM. 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA. Neurobiology of Aging. 33: 194.e5-15. PMID 20561716 DOI: 10.1016/j.neurobiolaging.2010.04.035  1
2011 Brotchie J, Jenner P. New approaches to therapy. International Review of Neurobiology. 98: 123-50. PMID 21907085 DOI: 10.1016/B978-0-12-381328-2.00005-5  1
2011 Huot P, Fox SH, Brotchie JM. The serotonergic system in Parkinson's disease. Progress in Neurobiology. 95: 163-212. PMID 21878363 DOI: 10.1016/j.pneurobio.2011.08.004  1
2011 Huot P, Brotchie JM. 5-HT(1A) receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: bridging the gap between serotonergic and glutamatergic mechanisms. Experimental Neurology. 231: 195-8. PMID 21819982 DOI: 10.1016/j.expneurol.2011.07.006  1
2011 Huot P, Fox SH, Newman-Tancredi A, Brotchie JM. Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism? The Journal of Pharmacology and Experimental Therapeutics. 339: 2-8. PMID 21784889 DOI: 10.1124/jpet.111.184093  1
2011 Hilker R, Brotchie JM, Chapman J. Pros and cons of a prion-like pathogenesis in Parkinson's disease. Bmc Neurology. 11: 74. PMID 21689433 DOI: 10.1186/1471-2377-11-74  1
2011 Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM. Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 7190-8. PMID 21562283 DOI: 10.1523/JNEUROSCI.1171-11.2011  1
2011 Koprich JB, Fox SH, Johnston TH, Goodman A, Le Bourdonnec B, Dolle RE, DeHaven RN, DeHaven-Hudkins DL, Little PJ, Brotchie JM. The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 1225-33. PMID 21465551 DOI: 10.1002/mds.23631  1
2011 Koprich JB, Johnston TH, Huot P, Reyes MG, Espinosa M, Brotchie JM. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein. Plos One. 6: e17698. PMID 21408191 DOI: 10.1371/journal.pone.0017698  1
2011 Thiele SL, Warre R, Khademullah CS, Fahana N, Lo C, Lam D, Talwar S, Johnston TH, Brotchie JM, Nash JE. Generation of a model of L-DOPA-induced dyskinesia in two different mouse strains. Journal of Neuroscience Methods. 197: 193-208. PMID 21352853 DOI: 10.1016/j.jneumeth.2011.02.012  1
2011 Warre R, Thiele S, Talwar S, Kamal M, Johnston TH, Wang S, Lam D, Lo C, Khademullah CS, Perera G, Reyes G, Sun XS, Brotchie JM, Nash JE. Altered function of glutamatergic cortico-striatal synapses causes output pathway abnormalities in a chronic model of parkinsonism. Neurobiology of Disease. 41: 591-604. PMID 20971190 DOI: 10.1016/j.nbd.2010.10.013  1
2011 Johnston TH, Huot P, Fox SH, Wakefield JD, Sykes KA, Bartolini WP, Milne GT, Pearson JP, Brotchie JM. Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics. 336: 423-30. PMID 20966038 DOI: 10.1124/jpet.110.169532  1
2011 Fox SH, Brotchie JM. Non-Dopaminergic Approaches to the Treatment of Parkinson's Disease Parkinson's Disease: Non-Motor and Non-Dopaminergic Features. 432-454. DOI: 10.1002/9781444397970.ch38  1
2010 Koprich JB, Johnston TH, Reyes MG, Sun X, Brotchie JM. Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease. Molecular Neurodegeneration. 5: 43. PMID 21029459 DOI: 10.1186/1750-1326-5-43  1
2010 Fox SH, Brotchie JM. The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future. Progress in Brain Research. 184: 133-57. PMID 20887873 DOI: 10.1016/S0079-6123(10)84007-5  1
2010 Johnston TH, Fox SH, Piggott MJ, Savola JM, Brotchie JM. The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 2084-93. PMID 20824735 DOI: 10.1002/mds.23172  1
2010 Huot P, Johnston TH, Darr T, Hazrati LN, Visanji NP, Pires D, Brotchie JM, Fox SH. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 1399-408. PMID 20629135 DOI: 10.1002/mds.23083  1
2010 Alachkar A, Brotchie JM, Jones OT. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites. Neuroscience Research. 68: 44-50. PMID 20542064 DOI: 10.1016/j.neures.2010.06.003  1
2010 Johnston TH, van der Meij A, Brotchie JM, Fox SH. Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 1379-90. PMID 20310030 DOI: 10.1002/mds.23069  1
2010 Alachkar A, Brotchie JM, Jones OT. Binding of dopamine and 3-methoxytyramine as l-DOPA metabolites to human alpha(2)-adrenergic and dopaminergic receptors. Neuroscience Research. 67: 245-9. PMID 20302892 DOI: 10.1016/j.neures.2010.03.008  1
2010 Johnston TH, Fox SH, McIldowie MJ, Piggott MJ, Brotchie JM. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics. 333: 865-73. PMID 20231306 DOI: 10.1124/jpet.110.166629  1
2010 Fox SH, Visanji N, Reyes G, Huot P, Gomez-Ramirez J, Johnston T, Brotchie JM. Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 37: 86-95. PMID 20169779  1
2010 Silverdale MA, Kobylecki C, Hallett PJ, Li Q, Dunah AW, Ravenscroft P, Bezard E, Brotchie JM. Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. Synapse (New York, N.Y.). 64: 177-80. PMID 19852073 DOI: 10.1002/syn.20739  1
2010 McIldowie MJ, Gandy MN, Skelton BW, Brotchie JM, Koutsantonis GA, Spackman MA, Piggott MJ. Physical and crystallographic characterisation of the mGlu5 antagonist MTEP and its monohydrochloride. Journal of Pharmaceutical Sciences. 99: 234-45. PMID 19499574 DOI: 10.1002/jps.21823  1
2010 Brotchie J. Antidyskinetic actions of amantadine in Parkinson's disease: Are benefits maintained in the long term? Expert Review of Neurotherapeutics. 10: 871-873. DOI: 10.1586/ern.10.70  1
2010 Gandy MN, McIldowie M, Lewis K, Wasik AM, Salomonczyk D, Wagg K, Millar ZA, Tindiglia D, Huot P, Johnston T, Thiele S, Nguyen B, Barnes NM, Brotchie JM, Martin-Iverson MT, et al. Redesigning the designer drug ecstasy: Non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity Medchemcomm. 1: 287-293. DOI: 10.1039/c0md00108b  1
2009 Koprich JB, Johnston TH, Huot P, Fox SH, Brotchie JM. New insights into the organization of the basal ganglia. Current Neurology and Neuroscience Reports. 9: 298-304. PMID 19515282 DOI: 10.1007/s11910-009-0045-2  1
2009 Fox SH, Chuang R, Brotchie JM. Serotonin and Parkinson's disease: On movement, mood, and madness. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 1255-66. PMID 19412960 DOI: 10.1002/mds.22473  1
2009 Brotchie J, Fitzer-Attas C. Mechanisms compensating for dopamine loss in early Parkinson disease Neurology. 72: S32-S38. PMID 19221312 DOI: 10.1212/WNL.0b013e318198e0e9  1
2009 Visanji NP, Fox SH, Johnston T, Reyes G, Millan MJ, Brotchie JM. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease. Neurobiology of Disease. 35: 184-92. PMID 19118628 DOI: 10.1016/j.nbd.2008.11.010  1
2009 Visanji NP, Fox SH, Johnston TH, Millan MJ, Brotchie JM. Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques. The Journal of Pharmacology and Experimental Therapeutics. 328: 276-83. PMID 18955589 DOI: 10.1124/jpet.108.144097  1
2008 Fox SH, Brotchie JM, Lang AE. Non-dopaminergic treatments in development for Parkinson's disease. The Lancet. Neurology. 7: 927-38. PMID 18848312 DOI: 10.1016/S1474-4422(08)70214-X  1
2008 Fox SH, Chuang R, Brotchie JM. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy. Progress in Brain Research. 172: 479-94. PMID 18772047 DOI: 10.1016/S0079-6123(08)00923-0  1
2008 Visanji NP, de Bie RM, Johnston TH, McCreary AC, Brotchie JM, Fox SH. The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 1922-5. PMID 18759357 DOI: 10.1002/mds.22086  1
2008 Lopez S, Turle-Lorenzo N, Johnston TH, Brotchie JM, Schann S, Neuville P, Amalric M. Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats. Neuropharmacology. 55: 483-90. PMID 18625257 DOI: 10.1016/j.neuropharm.2008.06.038  1
2008 Robb EL, Winkelmolen L, Visanji N, Brotchie J, Stuart JA. Dietary resveratrol administration increases MnSOD expression and activity in mouse brain Biochemical and Biophysical Research Communications. 372: 254-259. PMID 18486604 DOI: 10.1016/j.bbrc.2008.05.028  1
2008 Nicholas AP, Lubin FD, Hallett PJ, Vattem P, Ravenscroft P, Bezard E, Zhou S, Fox SH, Brotchie JM, Sweatt JD, Standaert DG. Striatal histone modifications in models of levodopa-induced dyskinesia. Journal of Neurochemistry. 106: 486-94. PMID 18410512 DOI: 10.1111/j.1471-4159.2008.05417.x  1
2008 Visanji NP, Orsi A, Johnston TH, Howson PA, Dixon K, Callizot N, Brotchie JM, Rees DD. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 22: 2488-97. PMID 18364399 DOI: 10.1096/fj.07-095398  1
2008 Lee J, Gomez-Ramirez J, Johnston TH, Visanji N, Brotchie JM. Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease. Synapse (New York, N.Y.). 62: 310-3. PMID 18241048 DOI: 10.1002/syn.20481  1
2008 Jugloff DG, Vandamme K, Logan R, Visanji NP, Brotchie JM, Eubanks JH. Targeted delivery of an Mecp2 transgene to forebrain neurons improves the behavior of female Mecp2-deficient mice. Human Molecular Genetics. 17: 1386-96. PMID 18223199 DOI: 10.1093/hmg/ddn026  1
2008 Brotchie JM. Pharmacology of Parkinson's Disease Therapeutics of Parkinson's Disease and Other Movement Disorders. 37-48. DOI: 10.1002/9780470713990.ch3  1
2007 Shin DS, Samoilova M, Cotic M, Zhang L, Brotchie JM, Carlen PL. High frequency stimulation or elevated K+ depresses neuronal activity in the rat entopeduncular nucleus. Neuroscience. 149: 68-86. PMID 17826920 DOI: 10.1016/j.neuroscience.2007.06.055  1
2007 Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Movement Disorders : Official Journal of the Movement Disorder Society. 22: 1379-89; quiz 1523. PMID 17427940 DOI: 10.1002/mds.21475  1
2007 Hallett PJ, Brotchie JM. Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia. Movement Disorders : Official Journal of the Movement Disorder Society. 22: 28-40. PMID 17089424 DOI: 10.1002/mds.21163  1
2006 Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Le Novère N, Obeso JA, Schwarzschild MA, Spampinato U, Davidai G. Novel pharmacological targets for the treatment of Parkinson's disease. Nature Reviews. Drug Discovery. 5: 845-54. PMID 17016425 DOI: 10.1038/nrd2087  1
2006 Hill MP, Ravenscroft P, McGuire SG, Brotchie JM, Crossman AR, Rochat C, Millan MJ. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 2090-5. PMID 16991143 DOI: 10.1002/mds.21106  1
2006 Fox SH, Visanji NP, Johnston TH, Gomez-Ramirez J, Voon V, Brotchie JM. Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. Archives of Neurology. 63: 1343-4. PMID 16966523 DOI: 10.1001/archneur.63.9.1343  1
2006 Visanji NP, Gomez-Ramirez J, Johnston TH, Pires D, Voon V, Brotchie JM, Fox SH. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 1879-91. PMID 16960862 DOI: 10.1002/mds.21073  1
2006 Nadjar A, Brotchie JM, Guigoni C, Li Q, Zhou SB, Wang GJ, Ravenscroft P, Georges F, Crossman AR, Bezard E. Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 8653-61. PMID 16928853 DOI: 10.1523/JNEUROSCI.2582-06.2006  1
2006 Fox SH, Lang AE, Brotchie JM. Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 1578-94. PMID 16874752 DOI: 10.1002/mds.20936  1
2006 Visanji NP, Millan MJ, Brotchie JM. Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats. Experimental Neurology. 202: 85-92. PMID 16814282 DOI: 10.1016/j.expneurol.2006.05.016  1
2006 Lee J, Di Marzo V, Brotchie JM. A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats. Neuropharmacology. 51: 557-65. PMID 16806299 DOI: 10.1016/j.neuropharm.2006.04.016  1
2006 Gomez-Ramirez J, Johnston TH, Visanji NP, Fox SH, Brotchie JM. Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 839-46. PMID 16532454 DOI: 10.1002/mds.20828  1
2006 Johnston TH, Brotchie JM. Drugs in development for Parkinson's disease: an update. Current Opinion in Investigational Drugs (London, England : 2000). 7: 25-32. PMID 16425668  1
2006 Alachkar A, Brotchie J, Jones OT. α2-Adrenoceptor-mediated modulation of the release of GABA and noradrenaline in the rat substantia nigra pars reticulata Neuroscience Letters. 395: 138-142. PMID 16356632 DOI: 10.1016/j.neulet.2005.10.069  1
2005 Visanji NP, Brotchie JM. MPTP-induced models of Parkinson's disease in mice and non-human primates. Current Protocols in Pharmacology / Editorial Board, S.J. Enna (Editor-in-Chief) ... [Et Al.]. Unit5.42. PMID 21953394 DOI: 10.1002/0471141755.ph0542s29  1
2005 Johnston TH, Fox SH, Brotchie JM. Advances in the delivery of treatments for Parkinson's disease. Expert Opinion On Drug Delivery. 2: 1059-73. PMID 16296809 DOI: 10.1517/17425247.2.6.1059  1
2005 Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Movement Disorders : Official Journal of the Movement Disorder Society. 20: 919-31. PMID 16007614 DOI: 10.1002/mds.20612  1
2005 Venderova K, Brown TM, Brotchie JM. Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus. Experimental Neurology. 194: 284-7. PMID 15899265 DOI: 10.1016/j.expneurol.2005.02.012  1
2005 van der Stelt M, Fox SH, Hill M, Crossman AR, Petrosino S, Di Marzo V, Brotchie JM. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 19: 1140-2. PMID 15894565 DOI: 10.1096/fj.04-3010fje  1
2005 Hallett PJ, Dunah AW, Ravenscroft P, Zhou S, Bezard E, Crossman AR, Brotchie JM, Standaert DG. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology. 48: 503-16. PMID 15755478 DOI: 10.1016/j.neuropharm.2004.11.008  1
2005 Nash JE, Johnston TH, Collingridge GL, Garner CC, Brotchie JM. Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 19: 583-5. PMID 15703272 DOI: 10.1096/fj.04-1854fje  1
2005 Johnston TH, Lee J, Gomez-Ramirez J, Fox SH, Brotchie JM. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease. Experimental Neurology. 191: 243-50. PMID 15649479 DOI: 10.1016/j.expneurol.2004.10.002  1
2005 Brotchie JM, Lee J, Venderova K. Levodopa-induced dyskinesia in Parkinson's disease. Journal of Neural Transmission (Vienna, Austria : 1996). 112: 359-91. PMID 15614429 DOI: 10.1007/s00702-004-0251-7  1
2005 Silverdale MA, Nicholson SL, Crossman AR, Brotchie JM. Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 20: 403-9. PMID 15593312 DOI: 10.1002/mds.20345  1
2004 Hill MP, Brotchie JM, Crossman AR, Bezard E, Michel A, Grimée R, Klitgaard H. Levetiracetam Interferes With the L-dopa priming process in MPTP-lesioned drug-naive marmosets. Clinical Neuropharmacology. 27: 171-7. PMID 15319703 DOI: 10.1097/01.wnf.0000135478.70905.3d  1
2004 Johnston TH, Brotchie JM. Drugs in development for Parkinson's disease. Current Opinion in Investigational Drugs (London, England : 2000). 5: 720-6. PMID 15298067  1
2004 Nash JE, Ravenscroft P, McGuire S, Crossman AR, Menniti FS, Brotchie JM. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Experimental Neurology. 188: 471-9. PMID 15246846 DOI: 10.1016/j.expneurol.2004.05.004  1
2004 Silverdale MA, Nicholson SL, Ravenscroft P, Crossman AR, Millan MJ, Brotchie JM. Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate. Experimental Neurology. 188: 128-38. PMID 15191809 DOI: 10.1016/j.expneurol.2004.03.022  1
2004 Obeso JA, Rodriguez-Oroz MC, Lanciego JL, Rodriguez Diaz M. How does Parkinson's disease begin? The role of compensatory mechanisms. Trends in Neurosciences. 27: 125-7; author reply . PMID 15036875 DOI: 10.1016/j.tins.2003.12.006  1
2004 Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics. 310: 386-94. PMID 15004218 DOI: 10.1124/jpet.104.066191  1
2004 Bezard E, Hill MP, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. European Journal of Pharmacology. 485: 159-64. PMID 14757136 DOI: 10.1016/j.ejphar.2003.11.065  1
2004 Ravenscroft P, Chalon S, Brotchie JM, Crossman AR. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. Experimental Neurology. 185: 36-46. PMID 14697317 DOI: 10.1016/j.expneurol.2003.09.001  1
2003 Brown TM, Brotchie JM, Fitzjohn SM. Cannabinoids decrease corticostriatal synaptic transmission via an effect on glutamate uptake. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 11073-7. PMID 14657164  1
2003 Hill MP, Bezard E, McGuire SG, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Movement Disorders : Official Journal of the Movement Disorder Society. 18: 1301-5. PMID 14639671 DOI: 10.1002/mds.10542  1
2003 Henry B, Duty S, Fox SH, Crossman AR, Brotchie JM. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Experimental Neurology. 183: 458-68. PMID 14552886 DOI: 10.1016/S0014-4886(03)00064-5  1
2003 Bezard E, Baufreton J, Owens G, Crossman AR, Dudek H, Taupignon A, Brotchie JM. Sonic hedgehog is a neuromodulator in the adult subthalamic nucleus. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 17: 2337-8. PMID 14525941 DOI: 10.1096/fj.03-0291fje  1
2003 Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 18: 872-83. PMID 12889076 DOI: 10.1002/mds.10464  1
2003 Bezard E, Gross CE, Brotchie JM. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends in Neurosciences. 26: 215-21. PMID 12689773 DOI: 10.1016/S0166-2236(03)00038-9  1
2003 Brotchie JM. CB1 cannabinoid receptor signalling in Parkinson's disease. Current Opinion in Pharmacology. 3: 54-61. PMID 12550742 DOI: 10.1016/S1471-4892(02)00011-5  1
2003 Segovia G, Mora F, Crossman AR, Brotchie JM. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 18: 138-49. PMID 12539206 DOI: 10.1002/mds.10312  1
2003 Silverdale MA, Fox SH, Crossman AR, Brotchie JM. Potential nondopaminergic drugs for Parkinson's disease. Advances in Neurology. 91: 273-91. PMID 12442686  1
2002 Nicholson SL, Brotchie JM. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 9: 1-6. PMID 12464115 DOI: 10.1046/j.1468-1331.2002.00272.x  1
2002 Nash JE, Brotchie JM. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat. Movement Disorders : Official Journal of the Movement Disorder Society. 17: 455-66. PMID 12112191 DOI: 10.1002/mds.10107  1
2002 Silverdale MA, Crossman AR, Brotchie JM. Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia. Experimental Neurology. 174: 21-8. PMID 11869030 DOI: 10.1006/exnr.2001.7854  1
2002 Fox SH, Kellett M, Moore AP, Crossman AR, Brotchie JM. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Movement Disorders : Official Journal of the Movement Disorder Society. 17: 145-9. PMID 11835452 DOI: 10.1002/mds.1280  1
2001 Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology. 57: 2108-11. PMID 11739835  1
2001 Hille CJ, Fox SH, Maneuf YP, Crossman AR, Brotchie JM. Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease. Experimental Neurology. 172: 189-98. PMID 11681851 DOI: 10.1006/exnr.2001.7763  1
2001 Henry B, Fox SH, Crossman AR, Brotchie JM. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Experimental Neurology. 171: 139-46. PMID 11520128 DOI: 10.1006/exnr.2001.7727  1
2001 Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 21: 6853-61. PMID 11517273  1
2001 Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nature Reviews. Neuroscience. 2: 577-88. PMID 11484001 DOI: 10.1038/35086062  1
2001 Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, Brotchie JM. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Movement Disorders : Official Journal of the Movement Disorder Society. 16: 642-50. PMID 11481687 DOI: 10.1002/mds.1148  1
2001 Silverdale MA, McGuire S, McInnes A, Crossman AR, Brotchie JM. Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Experimental Neurology. 169: 400-6. PMID 11358453 DOI: 10.1006/exnr.2001.7649  1
2001 Bezard E, Boraud T, Chalon S, Brotchie JM, Guilloteau D, Gross CE. Pallidal border cells: an anatomical and electrophysiological study in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey. Neuroscience. 103: 117-23. PMID 11311792 DOI: 10.1016/S0306-4522(00)00546-7  1
2001 Bezard E, Ravenscroft P, Gross CE, Crossman AR, Brotchie JM. Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys. Neurobiology of Disease. 8: 343-50. PMID 11300729 DOI: 10.1006/nbdi.2000.0375  1
2001 Bezard E, Crossman AR, Gross CE, Brotchie JM. Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 15: 1092-4. PMID 11292678  1
2000 Hill MP, Hille CJ, Brotchie JM. Delta-opioid receptor agonists as a therapeutic approach in Parkinson's disease. Drug News & Perspectives. 13: 261-8. PMID 12937640  0.6
2000 Fox SH, Brotchie JM. 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 15: 1064-9. PMID 11104187 DOI: 10.1002/1531-8257(200011)15:6<1064::AID-MDS1002>3.0.CO;2-C  1
2000 Nash JE, Brotchie JM. A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 7782-9. PMID 11027242  1
2000 Nash JE, Fox SH, Henry B, Hill MP, Peggs D, McGuire S, Maneuf Y, Hille C, Brotchie JM, Crossman AR. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Experimental Neurology. 165: 136-42. PMID 10964492 DOI: 10.1006/exnr.2000.7444  1
2000 Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 14: 1432-8. PMID 10877836  1
2000 Fox SH, Brotchie JM. 5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat. European Journal of Pharmacology. 398: 59-64. PMID 10856448 DOI: 10.1016/S0014-2999(00)00238-7  1
2000 Brotchie JM. The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease. Annals of Neurology. 47: S105-12; discussion . PMID 10762137  1
2000 Hill MP, Hille CJ, Brotchie JM. δ-Opioid receptor agonists as a therapeutic approach in Parkinson's disease Drug News and Perspectives. 13: 261-268.  1
1999 Hill MP, Brotchie JM. The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat. British Journal of Pharmacology. 128: 1577-85. PMID 10602339 DOI: 10.1038/sj.bjp.0702943  1
1999 Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 14: 744-53. PMID 10495035 DOI: 10.1002/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7  1
1999 Brotchie JM, Fox SH. Quantitative assessment of dyskinesias in subhuman primates. Movement Disorders : Official Journal of the Movement Disorder Society. 14: 40-7. PMID 10493402  1
1999 Brotchie JM. Advances in understanding the neural mechanisms underlying L-DOPA-induced dyskinesia. Advances in Neurology. 80: 71-85. PMID 10410705  1
1999 Hill MP, Brotchie JM. Control of glutamate release by calcium channels and kappa-opioid receptors in rodent and primate striatum. British Journal of Pharmacology. 127: 275-83. PMID 10369483 DOI: 10.1038/sj.bjp.0702523  1
1999 Henry B, Crossman AR, Brotchie JM. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Experimental Neurology. 155: 204-20. PMID 10072296 DOI: 10.1006/exnr.1998.6996  1
1999 Nash JE, Hill MP, Brotchie JM. Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat. Experimental Neurology. 155: 42-8. PMID 9918703 DOI: 10.1006/exnr.1998.6963  1
1999 Fox SH, Brotchie JM. A role for 5-HT(2C) receptor antagonists in the treatment of Parkinson's disease? Drug News and Perspectives. 12: 477-483.  1
1998 Brotchie JM. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 871-6. PMID 9827609 DOI: 10.1002/mds.870130603  1
1998 Henry B, Crossman AR, Brotchie JM. Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of L-dopa-induced dyskinesia. Advances in Neurology. 78: 53-61. PMID 9750903  1
1998 Brotchie JM, Henry B, Hille CJ, Crossman AR. Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease. Advances in Neurology. 78: 41-52. PMID 9750902  1
1998 Crossman AR, Brotchie JM. Pathophysiology of dystonia. Advances in Neurology. 78: 19-25. PMID 9750899  1
1998 Richter A, Brotchie JM, Crossman AR, Löscher W. [3H]-2-deoxyglucose uptake study in mutant dystonic hamsters: abnormalities in discrete brain regions of the motor system. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 718-25. PMID 9686781 DOI: 10.1002/mds.870130419  1
1998 Henry B, Crossman AR, Brotchie JM. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Experimental Neurology. 151: 334-42. PMID 9628768 DOI: 10.1006/exnr.1998.6819  1
1998 Fox SH, Moser B, Brotchie JM. Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Experimental Neurology. 151: 35-49. PMID 9582253 DOI: 10.1006/exnr.1998.6792  1
1998 Hughes NR, McKnight AT, Woodruff GN, Hill MP, Crossman AR, Brotchie JM. Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 228-33. PMID 9539334 DOI: 10.1002/mds.870130206  1
1998 Duty S, Henry B, Crossman AR, Brotchie JM. Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat. Experimental Neurology. 150: 223-34. PMID 9527891 DOI: 10.1006/exnr.1997.6771  1
1997 Maneuf YP, Crossman AR, Brotchie JM. The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Experimental Neurology. 148: 265-70. PMID 9398468 DOI: 10.1006/exnr.1997.6645  1
1997 Brotchie JM. Novel approaches to the symptomatic treatment of parkinsonian syndromes: alternatives and adjuncts to dopamine-replacement. Current Opinion in Neurology. 10: 340-5. PMID 9266159  1
1997 Duty S, Brotchie JM. Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression. Experimental Neurology. 144: 423-32. PMID 9168843 DOI: 10.1006/exnr.1997.6431  1
1997 Maneuf YP, Brotchie JM. Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. British Journal of Pharmacology. 120: 1397-8. PMID 9113356 DOI: 10.1038/sj.bjp.0701101  1
1997 Glass M, Brotchie JM, Maneuf YP. Modulation of neurotransmission by cannabinoids in the basal ganglia. The European Journal of Neuroscience. 9: 199-203. PMID 9058040 DOI: 10.1111/j.1460-9568.1997.tb01390.x  0.8
1996 East SJ, Parry-Jones A, Brotchie JM. Ionotropic glutamate receptors and nitric oxide synthesis in the rat striatum. Neuroreport. 8: 71-5. PMID 9051755  1
1996 Fox SH, Brotchie JM. New treatments for movement disorders? Trends in Pharmacological Sciences. 17: 339-42. PMID 8979766 DOI: 10.1016/S0165-6147(96)30018-7  1
1996 Henry B, Brotchie JM. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease. Drugs & Aging. 9: 149-58. PMID 8877309  1
1996 Maneuf YP, Crossman AR, Brotchie JM. Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2. Synapse (New York, N.Y.). 22: 382-5. PMID 8867032 DOI: 10.1002/(SICI)1098-2396(199604)22:4<382::AID-SYN9>3.0.CO;2-7  1
1996 Maneuf YP, Nash JE, Crossman AR, Brotchie JM. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. European Journal of Pharmacology. 308: 161-4. PMID 8840127 DOI: 10.1016/0014-2999(96)00326-3  1
1996 Maneuf YP, Duty S, Hille CJ, Crossman AR, Brotchie JM. Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: implications for the treatment of Parkinson's disease. Experimental Neurology. 139: 12-6. PMID 8635558 DOI: 10.1006/exnr.1996.0075  1
1995 Mitchell IJ, Hughes N, Carroll CB, Brotchie JM. Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset. Behavioural Pharmacology. 6: 492-507. PMID 11224357  1
1995 Hill MP, Brotchie JM. Modulation of glutamate release by a kappa-opioid receptor agonist in rodent and primate striatum. European Journal of Pharmacology. 281: R1-R2. PMID 8566106 DOI: 10.1016/0014-2999(95)00385-X  1
1995 Carroll CB, Holloway V, Brotchie JM, Mitchell IJ. Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms. Psychopharmacology. 119: 55-65. PMID 7675950 DOI: 10.1007/BF02246054  1
1995 East SJ, Hill MP, Brotchie JM. Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes. European Journal of Pharmacology. 277: 117-21. PMID 7635167 DOI: 10.1016/0014-2999(95)00119-6  1
1995 Maneuf YP, Mitchell IJ, Crossman AR, Woodruff GN, Brotchie JM. Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Research. 683: 102-8. PMID 7552334 DOI: 10.1016/0006-8993(95)00358-W  1
1994 Maneuf YP, Mitchell IJ, Crossman AR, Brotchie JM. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Experimental Neurology. 125: 65-71. PMID 8307125 DOI: 10.1006/exnr.1994.1007  1
1991 Mitchell IJ, Brotchie JM, Brown GD, Crossman AR. Modeling the functional organization of the basal ganglia. A parallel distributed processing approach. Movement Disorders : Official Journal of the Movement Disorder Society. 6: 189-204. PMID 1922123 DOI: 10.1002/mds.870060302  1
1991 Brotchie JM, Crossman AR. D-[3H]aspartate and [14C]GABA uptake in the basal ganglia of rats following lesions in the subthalamic region suggest a role for excitatory amino acid but not GABA-mediated transmission in subthalamic nucleus efferents. Experimental Neurology. 113: 171-81. PMID 1651255 DOI: 10.1016/0014-4886(91)90173-A  1
1991 Brotchie JM, Mitchell IJ, Sambrook MA, Crossman AR. Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Movement Disorders : Official Journal of the Movement Disorder Society. 6: 133-8. PMID 1647492 DOI: 10.1002/mds.870060208  1
1990 Bevan MD, Brotchie JM, Crossman AR. Intracerebral injections of the EAA antagonist kynurenate in the entopeduncular nucleus of the rat elicits a range of hyperkinetic disorders European Journal of Pharmacology. 183: 943.  1
1990 Brotchie JM, Bevan MD, Mitchell IJ, Crossman AR. Anti-parkinsonian effects of EAA antagonists in the entopeduncular nucleus are due to an action at NMDA-like receptors European Journal of Pharmacology. 183: 943-944.  1
Show low-probability matches.